RxDoctor Payments Data

Dianna Deignan, MD

Family Medicine · Worcester, MANPI 1841219359

Payments from drug & device makers

$1,073in general payments, 2019–2025

Across 15 payments — averaging $71.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$290
  • Novo Nordisk$164
  • Neurocrine Biosciences, Inc.$127
  • Sanofi-aventis U.S. LLC$125
  • ANI Pharmaceuticals, Inc.$115
  • GSK$111
  • plus $141 from 3 others

What the payments were for

  • Food & beverage$1,02896%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,073 in reported general payments places this provider in the 85th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$127,520
Medicare patients
526
Services billed
2,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$54,819
OzempicSemaglutide46$51,245
EliquisApixaban32$41,406
XareltoRivaroxaban14$20,987
JanuviaSitagliptin Phosphate13$14,437
SynthroidLevothyroxine Sodium74$7,607
Spiriva HandihalerTiotropium Bromide12$6,184
SymbicortBudesonide/Formoterol Fumarate18$5,102
Atorvastatin Calcium433$5,060
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,039
Rosuvastatin Calcium384$4,921
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,570
Metoprolol Succinate194$3,012
Losartan Potassium278$2,989
Amlodipine Besylate454$2,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$164$51,24546 claims
PfizerEliquis$18$41,40632 claims
AbbVieSynthroid$78$7,60774 claims
AstraZenecaSymbicort$290$5,10218 claims
GSKAnoro Ellipta$111$5,03912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →